Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Icecure Medical ( (ICCM) ) has provided an update.
IceCure Medical has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This milestone indicates the company’s stabilized market position, potentially boosting investor confidence and supporting its operations and growth in the medical device industry.
More about Icecure Medical
IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors, focusing primarily on breast, kidney, bone, and lung cancer. Their ProSense® system offers a minimally invasive alternative to surgical tumor removal and is marketed globally, including in the U.S., Europe, and China.
YTD Price Performance: 5.69%
Average Trading Volume: 743,123
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $71.21M
For an in-depth examination of ICCM stock, go to TipRanks’ Stock Analysis page.
